ClinicalTrials.gg
RecruitingNCT05845138Updated Aug 1, 2023

A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.

A Phase 1/2 interventional study of SHR-A1811 for injection ; capecitabine in Breast Cancer, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 9 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-01.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
116
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies testing trastuzumab rezetecan in Breast Neoplasms — 45 open to participants now, 51 under way, 9 of them phase 3. trastuzumab rezetecan · Breast Neoplasms.

Planned enrollment
25th of 52
116 · median 106
Started
2023
with 8 others
Phase 1/2
7 of 52
6 open now
Primary completion
2024-12
later than 1 of 50 live
Registered
9th of 52
by date
Lead sponsor
2 of 52
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Among the 52 studies testing trastuzumab rezetecan in Breast Neoplasms, this one is the 25th largest by planned enrollment, is one of 9 that started in 2023, is one of 7 in phase 1/2, reaches primary completion later than 1 of the 50 other live ones, and was the 9th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

45 of the 52 studies testing trastuzumab rezetecan in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

39 more — sign in →

By country, each count listing its studies:

All 45 open studies →

Where they have run

About trastuzumab rezetecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing trastuzumab rezetecan in Breast Neoplasms, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics, and immunogenicity of SHR-A1811 combined with capecitabine in treatment of unresectable or metastatic breast cancer with low HER2 expression.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women aged 18 to 75 (inclusive).
  2. low expression unresectable or breast cancer confirmed by histology or cytology.
  3. score is 0 or 1.
  4. An expected survival of ≥ 12 weeks.
  5. At least one according to v1.1 criteria.
  6. Women of (WOCBP) subjects must agree to use highly effective for 7 months from the start of study screening until the last study medication and agree not to breastfeeding.
  7. Patients voluntarily joined the study and signed , had good compliance and willingness to cooperate with the visit and study related procedures.

Exclusion criteria

Exclusion Criteria:

  1. Have other within the past 5 years.
  2. Presence with uncontrollable third space effusion.
  3. Have surgical treatment, radiotherapy, chemotherapy, immunotherapy, molecular targeted therapy, biological therapy or other drug clinical studies within 4 weeks before the first medication.
  4. Accepted antibody drug conjugates containing etoisomercan derivative topoisomerase I inhibitor.
  5. cardiovascular disorders.
  6. Presence of active , , cirrhosis,or serious infected persons requiring antibiotic, antiviral or antifungal control.
  7. The toxicity from previous anti-tumor treatment has not recovered to ≤ grade I.
  8. Known to be allergic to any study drug or any of its , or to humanized monoclonal antibody products.
  9. Failure to swallow, chronic diarrhea, intestinal obstruction, or presence of other factors affecting drug administration and absorption.
  10. Presence of other serious physical or mental diseases or laboratory abnormalities.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    SHR-A1811 combined with capecitabine

    Drug: SHR-A1811 for injection ; capecitabine

Interventions

06

What researchers measure

Primary outcomes

  1. DLT(Phase I (dose exploration phase) ) [ Time Frame: 21 days after the first administration of each subject ]

    Time frame: 21 days after the first administration of each subject ]

  2. Incidence of AEs(Phase I (dose exploration phase) )

    Time frame: from Day1 to 40 days after last dose

  3. Incidence of SAEs(Phase I (dose exploration phase) )

    Time frame: from Day1 to 40 days after last dose

  4. Objective response rate(Phase II (efficacy expansion phase))

    Time frame: One year after the last subject was enrolled in the group

Secondary outcomes

  1. Duration of response(DoR )

    Time frame: One year after the last subject was enrolled in the group

  2. Progression Free Survival(PFS)

    Time frame: One year after the last subject was enrolled in the group

  3. Objective response rate(Phase I (dose exploration phase))

    Time frame: One year after the last subject was enrolled in the group

  4. Incidence of AEs(Phase II (efficacy expansion phase))

    Time frame: from Day1 to 40 days after last dose

  5. Incidence of SAEs(Phase II (efficacy expansion phase))

    Time frame: from Day1 to 40 days after last dose

07

Study locations

2 of 9 sites recruiting
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230000, China
    Not yet recruiting
    • Fanfan Li · Principal investigator
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijng 100000, China
    Recruiting
    • Fei Ma · Principal investigator
  • Guangxi Medical University Affiliated Tumor Hospital & Oncology Medical College
    Nanning, Guangxi 530000, China
    Not yet recruiting
    • Qinguo Mo · Principal investigator
  • Shantou Central Hospital
    Shantou, Guangzhou 515000, China
    Not yet recruiting
    • Zhiyong Wu · Principal investigator
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 450000, China
    Recruiting
    • Pilei Si · Principal investigator
  • The First Affiliated Hospital with Nanjing Medical University
    Nanjing, Jiangsu 210000, China
    Not yet recruiting
    • Yongmei Yin · Principal investigator
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110000, China
    Not yet recruiting
    • Yuee Teng · Principal investigator
  • Shandong Cancer Hospital&Institute
    Jinan, Shandong 250000, China
    Not yet recruiting
    • Huihui Li · Principal investigator
  • Wenzhou People's Hospital
    Wenzhou, Zhejiang 325000, China
    Not yet recruiting
    • Miaoyong Zhu · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Dec 2024, 17 months after the start.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 17 months is below that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2023
First posted
May 6, 2023
StartActual
Jul 25, 2023
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2025
Last update
Aug 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05845138
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Jul 25, 2023
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Aug 1, 2023

Study contacts

Shuchao Wu
Contact
shuchao.wu@hengrui.com
+0518-81220121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab rezetecan · Capecitabine

Start the discussion